Tablet splitting of narrow therapeutic index drugs: a nationwide survey in Taiwan
- 465 Downloads
Background Tablet splitting or pill splitting frequently occurs in daily medical practice. For drugs with special pharmacokinetic characters, such as drugs with narrow therapeutic index (NTI), unequal split tablets might lead to erroneous dose titration and it even cause toxicity. Objective The aim of this study was to investigate the frequency of prescribing split NTI drugs at ambulatory setting in Taiwan. Setting A population-based retrospective study was conducted using the National Health Insurance Research Database in Taiwan. All ambulatory visits were analyzed from the longitudinal cohort datasets of the National Health Insurance Research Database. Methods The details of ambulatory prescriptions containing NTI drugs were extracted by using the claims datasets of one million beneficiaries from National Healthcare Insurance Research Database in 2010 in Taiwan. The analyses were stratified by dosage form, patient age and the number of prescribed tablets in a single dose for each NTI drugs. Main outcome measures Number and distinct dosage forms of available NTI drug items in Taiwan, number of prescriptions involved split NTI drugs, and number of patients received split NTI drugs. Results A total of 148,548 patients had received 512,398 prescriptions of NTI drugs and 41.8 % (n = 62,121) of patients had received 36.3 % (n = 185,936) of NTI drug prescriptions in form of split tablets. The percentage of splitting was highest in digoxin prescriptions (81.0 %), followed by warfarin (72.0 %). In the elderly patients, split tablets were very prevalent with digoxin (82.4 %) and warfarin (84.5 %). Conclusion NTI drugs were frequently prescribed to be taken in split forms in Taiwan. Interventions may be needed to provide effective and convenient NTI drug use. Further studies are needed to evaluate the clinical outcome of inappropriate split NTI drugs.
KeywordsNarrow therapeutic index drugs Prescribing patterns Splitting frequency Tablet splitting Taiwan
This study is based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health and managed by National Health Research Institutes, Taiwan. The interpretation and conclusions contained herein do not represent those of Bureau of National Health Insurance, Department of Health or National Health Research Institutes.
This study was supported by Grants from Taipei Veterans General Hospital (V102C-160) and National Science Council in Taiwan (NSC 99-2410-H-004-029-MY3).
Conflicts of interest
The authors declare that they have no conflicts of interest.
- 3.Quinzler R, Schmitt SP, Pritsch M, Kaltschmidt J, Haefeli WE. Substantial reduction of inappropriate tablet splitting with computerised decision support: a prospective intervention study assessing potential benefit and harm. BMC Med Inform Decis Mak. 2009;9:30. doi: 10.1186/1472-6947-9-30 (eCollection 2009).PubMedCentralCrossRefPubMedGoogle Scholar
- 10.Jiang W, Yu LX. Bioequivalence for narrow therapeutic index drugs. In: Yu L, Li B, editors. FDA bioequivalence standards. New York: Springer; 2014. p. 191–216.Google Scholar
- 12.Clark NP, Witt DM, Delate T, Trapp M, Garcia D, Ageno W, et al. Warfarin-associated research projects and other endeavors consortium. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study. Pharmacotherapy. 2008;28(8):960–7.CrossRefPubMedGoogle Scholar
- 13.Blix HS, Viktil KK, Moger TA, Reikvam A. Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients. Pharm Pract (Internet). 2009;8(1):50–55. PMCID: PMC4140577.Google Scholar
- 18.Bureau of National Health Insurance, Department of Health, Executive Yuan, “The National Health Insurance Statistics,” 2010. http://www.nhi.gov.tw/English/webdata/webdata.aspx?menu=11&menu_id=296&WD_ID=296&webdata_id=4010. Accessed Aug 3 2015.
- 20.Narrow therapeutic index drugs designated by the north carolina secretary of human resources. North Carolina Register. 2013;27(13):1263.Google Scholar
- 25.Information Product. Lanoxin, digoxin 2006. Greenville: GlaxoSmith-Kline; 2006.Google Scholar